The evolution of human immunodeficiency virus (HIV) treatment has improved our
understanding and management of complex pharmacological issues that have driven …

In patients infected by HIV, the efficacy of highly active antiretroviral (ARV) therapy through
the blockade of different steps of the retrovirus life cycle is now well established. As HIV is a …

Objectives: To describe first dose and steady state antiretroviral drug exposure in the female
genital tract. Design: Non-blinded, single center, open-label pharmacokinetic study in HIV …

Objective: The aim of the study was to investigate relationships among indinavir, lamivudine-
triphosphate, and zidovudine-triphosphate pharmacokinetics and pharmacodynamics with …

Therapeutic drug monitoring (TDM) has been proposed as a means to optimise response to
highly active antiretroviral therapy (HAART) in HIV infection. Protease inhibitors (PIs) and the …

HIV resides within anatomical 'sanctuary sites', where local drug exposure and viral
dynamics may differ significantly from the systemic compartment. Suboptimal anti-retroviral …

3′-Azido-3′-deoxythymidine (AZT) is the first clinically effective drug for the treatment of
human immunodeficiency virus infection. The drug interaction with human serum albumin …

Objectives: Nucleoside analog reverse transcriptase inhibitors (NRTI) are used in virtually all
anti-HIV regimens. Clinical response depends on the intracellular formation of the …

Background Despite the efficacy of combination antiretroviral therapy (ART) and the
improvement in prognosis of those living with HIV/AIDS, a large proportion of individuals on …

Background: Both virological failure and the toxicity of HIV protease inhibitors have been
related to interindividual variability of plasma drug concentrations. Therapeutic drug …